EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

J Raaijmakers iD, S Salillas, R Aarnoutse, E Svensson, L Te Brake, R Stemkens iD, H Wertheim, W Hoefsloot, J van Ingen iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01464-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von J Raaijmakers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radboudumc Community for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Clofazimine, Diarylquinolines, Azithromycin, Ethambutol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bedaquiline has been proposed as a second-line drug to treat pulmonary disease caused by Mycobacterium avium complex. Based on in vitro synergy and interactions, a logical regimen would combine bedaquiline and clofazimine as additions to an ethambutol-azithromycin backbone. Here, we evaluate the added benefit of bedaquiline in a regimen of azithromycin, ethambutol, and clofazimine. THP-1 cells infected with M. avium ATCC 700898 were seeded in a hollow-fiber model and exposed to a regimen of azithromycin, ethambutol, and clofazimine with or without bedaquiline for 3 weeks. Epithelial lining fluid pharmacokinetic profiles of azithromycin and ethambutol were simulated, while an average steady-state concentration was sought for clofazimine and bedaquiline. Pharmacokinetics and pharmacodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug regimen was 0.65 (95% CI 0.63–0.67) and for the 4-drug regimen 0.65 (95% CI 0.64–0.67). The intracellular kill rate was 0.48 (95% CI 0.46–0.50) for the 3-drug regimen and 0.48 (95% CI 0.46–0.50) for the 4-drug regimen. Macrolide-tolerant subpopulations were observed with both treatment regimens at day 21. Bedaquiline does not add killing activity to a clofazimine-ethambutol-azithromycin regimen and did not improve suppression of the emergence of macrolide resistance, which makes its role as a second-line agent doubtful.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofazimineDiarylquinolinesAzithromycinEthambutolAntitubercular AgentsMycobacterium avium ComplexMycobacterium aviumHumansMicrobial Sensitivity TestsTHP-1 CellsDrug Synergism

Stichwörter der Autor:innen

M. aviumPK/PDbedaquilinehollow-fiber systemnontuberculous mycobacteria

Substanzen

ClofaziminebedaquilineDiarylquinolinesAzithromycinEthambutolAntitubercular Agents

Autor:innen und Institutionen

  • Radboudumc Community for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Aragon, Spain.
  • Radboudumc Community for Infectious Diseases, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Pharmacy, Uppsala University, Uppsala, Uppsala County, Sweden.
  • Radboudumc Community for Infectious Diseases, Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: J Raaijmakers, R Stemkens, J van Ingen

Zitieren

APA

Raaijmakers, J., Salillas, S., Aarnoutse, R., Svensson, E., Te Brake, L., Stemkens, R., Wertheim, H., Hoefsloot, W., & van Ingen, J. (2025). Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01464-24

Vancouver

Raaijmakers J, Salillas S, Aarnoutse R, Svensson E, Te Brake L, Stemkens R, et al. Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01464-24

BibTeX
@article{Raaijmakers2025,
  author = {Raaijmakers, J and Salillas, S and Aarnoutse, R and Svensson, E and Te Brake, L and Stemkens, R and Wertheim, H and Hoefsloot, W and van Ingen, J},
  title = {Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01464-24}
}
Kostenlos starten →